Virtu Financial’s Amicus Therapeutics FOLD Stock Holding History

Virtu Financial’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-117,063	Closed	-$1.67M	–	1854
2025 Q4	$1.67M	Buy	117,063 +74,902	+178%	+$736K	0.06%	201
2025 Q3	$332K	Buy	+42,161	New	+$300K	0.02%	704
2025 Q2	–	Sell	-28,571	Closed	-$233K	–	1656
2025 Q1	$233K	Buy	+28,571	New	+$264K	0.01%	751
2024 Q4	–	Sell	-10,046	Closed	-$107K	–	1704
2024 Q3	$107K	Buy	+10,046	New	+$109K	0.01%	898
2021 Q4	–	Sell	-55,191	Closed	-$527K	–	1868
2021 Q3	$527K	Buy	55,191 +38,708	+235%	+$396K	0.05%	439
2021 Q2	$159K	Buy	+16,483	New	+$161K	0.02%	1070
2019 Q4	–	Sell	-29,880	Closed	-$240K	–	1569
2019 Q3	$240K	Buy	+29,880	New	+$324K	0.02%	873
2019 Q2	–	Sell	-16,982	Closed	-$231K	–	1591
2019 Q1	$231K	Sell	16,982 -3,984	-19%	-$48.7K	0.01%	926
2018 Q4	$201K	Buy	+20,966	New	+$230K	0.01%	961

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Virtu Financial's FOLD Position: Q1 2026 in Review

Virtu Financial sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 117,063 shares — an estimated $1.67M sold.

Virtu Financial first reported a position in FOLD in Q4 2018 and held it in 9 quarters. The position peaked at $1.67M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Virtu Financial reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Virtu Financial sold 117,063 Amicus Therapeutics shares in Q1 2026, an estimated $1.67M.
Virtu Financial first reported a position in Amicus Therapeutics in Q4 2018 and held it in 9 quarters.
Virtu Financial's Amicus Therapeutics position peaked at $1.67M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.